Department of Orthopaedic Surgery, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam, Republic of Korea.
Department of Orthopaedic Surgery, Konkuk University School of Medicine, Seoul, Republic of Korea.
J Shoulder Elbow Surg. 2018 May;27(5):777-785. doi: 10.1016/j.jse.2017.11.019. Epub 2018 Jan 11.
This study evaluated the effect of systemic injection of recombinant human growth hormone (rhGH) on outcomes after arthroscopic rotator cuff repair.
This multicenter, prospective, randomized, comparative trial, randomized patients who underwent arthroscopic repair of large-sized rotator cuff tears into 3 groups: rhGH 4 mg group (n = 26), rhGH 8 mg group (n = 24) , and control group (n = 26). Sustained release rhGH was injected subcutaneously once weekly for 3 months postoperatively. The healing failure rate (primary end point), fatty infiltration, and atrophy of the supraspinatus muscle, and functional scores (Constant and American Shoulder and Elbow Surgeons scores) were evaluated at 6 months. Range of motion, pain visual analog scale, and serum insulin-like growth factor-1 level were measured at each follow-up.
The healing failure rate was similar between groups (rhGH 4 mg group, 30.8%; rhGH 8 mg group, 16.7%; and control group, 34.6%; all P > .05) The proportion of severe fatty infiltration (Goutallier grade ≥3) was 20.8% in the rhGH 8 mg group, 23.1% in the rhGH 4 mg group, and 34.6% in the control group (P > .05). Functional outcomes, range of motion, and pain visual analog scale were similar between groups (all P > .05). The rhGH 8 mg group showed more increased peak insulin-like growth factor-1 level (279.43 ng/mL) than the rhGH 4 mg group ((196.82 ng/mL) and control group (186.31 ng/mL), which was not statistically different (all P > .05). No rhGH injection-related major safety issues occurred.
This preliminary study showed no statistically significant improvement in healing or outcomes related to the treatment of rhGH after rotator cuff repair. However, further study with more enrolled patients after resetting the rhGH dose or daily administration protocol would be mandatory.
本研究评估了系统性注射重组人生长激素(rhGH)对关节镜肩袖修复术后结果的影响。
这是一项多中心、前瞻性、随机、对照试验,将接受关节镜修复大型肩袖撕裂的患者随机分为 3 组:rhGH 4mg 组(n=26)、rhGH 8mg 组(n=24)和对照组(n=26)。术后每周皮下注射一次持续释放 rhGH,持续 3 个月。6 个月时评估愈合失败率(主要终点)、冈上肌脂肪浸润和萎缩以及功能评分(Constant 和美国肩肘外科医生评分)。在每次随访时测量运动范围、疼痛视觉模拟评分和血清胰岛素样生长因子-1 水平。
各组愈合失败率相似(rhGH 4mg 组 30.8%;rhGH 8mg 组 16.7%;对照组 34.6%;均 P>.05)。rhGH 8mg 组严重脂肪浸润(Goutallier 分级≥3)比例为 20.8%,rhGH 4mg 组为 23.1%,对照组为 34.6%(均 P>.05)。功能结果、运动范围和疼痛视觉模拟评分在各组之间相似(均 P>.05)。rhGH 8mg 组的峰值胰岛素样生长因子-1 水平(279.43ng/mL)较 rhGH 4mg 组(196.82ng/mL)和对照组(186.31ng/mL)升高更为明显,但差异无统计学意义(均 P>.05)。未发生与 rhGH 注射相关的重大安全问题。
本初步研究显示,肩袖修复后 rhGH 治疗在愈合或结果方面无统计学显著改善。然而,需要进一步研究更多患者,重新设定 rhGH 剂量或每日给药方案。